Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 497 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia, Schizoaffective Disorder Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
Magstim Rapid-2 system triggering Magstim Super Rapid system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
risperidone, olanzapine, quetiapine, ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Mood Disorder, Psychotic
Interventions
mobile Social Interaction Therapy by Exposure (mSITE)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions
quetiapine, olanzapine, risperidone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced May 22, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced May 22, 2026, 4:15 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
curcumin 1800mg, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-cycloserine, glycine, placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 22, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Bellflower, California • Garden Grove, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia, Schizoaffective Disorder
Interventions
Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
Behavioral · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
adjunctive treatment with buspirone, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced May 22, 2026, 4:15 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Schizoaffective Disorder, Psychotic Disorder
Interventions
Placebo, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
15
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions
EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
Health Care Management and Supported Rehabilitation
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older · Female only
Enrollment
180 participants
Timeline
2001 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts • Nashua, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced May 22, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced May 22, 2026, 4:15 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CDR Computerized Cognitive Assessment System, MATRICS Consensus Cognitive Battery
Other
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced May 22, 2026, 4:15 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Emotional working memory training, Placebo working memory training
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced May 22, 2026, 4:15 AM EDT